EyePoint Pharmaceuticals

Press Releases

EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
Oct 15, 2018
- The first long-lasting, FDA approved micro-insert for up to three years of continuous control in chronic, non-infectious posterior segment uveitis, the third leading cause of blindness in the U.S.  - Company to host conference call today at 8:30 a.m. ET WATERTOWN, Mass. , Oct.
EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants
Oct 01, 2018
WATERTOWN, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has received proceeds of $28.9 million from the
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
Sep 12, 2018

-Substantial progress made in the Company’s accelerated transformation into a commercial entity -YUTIQ™ PDUFA date of November 5, 2018 -Commercial preparations underway for launch of DEXYCU™ in the first half of calendar year 2019 -Balance sheet strengthened by $35 million of capital led by EW

EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors
Sep 10, 2018
WATERTOWN, Mass. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company’s Board of Directors has elected Göran Ando, M.D., as its
EyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU™
Sep 05, 2018
WATERTOWN, Mass. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved
EyePoint Pharmaceuticals Announces Fiscal 2018 Fourth Quarter & Full Year Financial Results Release Date and Conference Call Information
Sep 05, 2018
WATERTOWN, Mass. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fiscal 2018 fourth quarter and full year on Wednesday,
EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 28, 2018
WATERTOWN, Mass. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled
EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality
Aug 15, 2018
- Senior Pharmaceutical Industry Executive with Extensive Experience Leading Regulatory Affairs - WATERTOWN, Mass. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative
EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 03, 2018
WATERTOWN, Mass. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported the grant of inducement awards to David Price , EyePoint’s newly
EyePoint Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
Aug 02, 2018
WATERTOWN, Mass. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that David Price , Chief Financial Officer, is scheduled to present an
EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officer
Aug 01, 2018
Seasoned financial executive brings more than 25 years of diverse financial and operational experience WATERTOWN, Mass. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative
EyePoint Pharmaceuticals Announces Presentation of Data Highlighting YUTIQ™ for Posterior Segment Uveitis at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
Jul 25, 2018
YUTIQ ™ delivers positive twelve month efficacy vs sham with reduced rates of recurrence and reduced use of rescue therapies in patients with noninfectious posterior segment uveitis NDA currently under review by FDA ; PDUFA action date of November 5, 2018 WATERTOWN, Mass.
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
Jul 11, 2018
WATERTOWN, Mass. , July 11, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that three abstracts supporting the Company's YUTIQ™ (fluocinolone
EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors
Jun 26, 2018
WATERTOWN, Mass. , June 26, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company developing and commercializing innovative ophthalmic products, today announced the appointment of Göran Ando, M.D., to the Company’s Board of Directors. Dr.
EyePoint Pharmaceuticals Announces Stockholder Approval of Second Tranche of Capital Financing
Jun 25, 2018
Expected closing of $25.5 million in capital to be used to accelerate EyePoint’s transformation into a commercial-stage specialty biopharmaceutical company Financing supports two near-term product launches anticipated in the first half of 2019 WATERTOWN, Mass.
EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S.
May 16, 2018
WATERTOWN, Mass. , May 16, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of Leonard M.
EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results
May 08, 2018
Completed Substantive Strategic Initiatives to Accelerate Transformation to a Commercial Company Conference Call and Webcast Today, May 8th , at 4:30 p.m. ET WATERTOWN, Mass. , May 08, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed
EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Apr 19, 2018
WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter of fiscal year 2018 on Tuesday, May 8, 2018.
EyePoint Pharmaceuticals' YUTIQ™ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Apr 18, 2018
WATERTOWN, Mass. , April 18, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ™ (fluocinolone
EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™
Apr 12, 2018
WATERTOWN, Mass. , April 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the U.S.
Displaying 1 - 20 of 318
EyePoint Pharmaceuticals